ReviewCurrent hypertension reports2003
Role of endothelin-1 in hypertension.
Review in Current hypertension reports, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 72 citations in OpenAlex.
- Endothelin receptor antagonists in chronic kidney disease.Nature reviews. Nephrology · 2025Review
- A Multivariate prediction model for amlodipine therapeutic efficacy in pediatric primary hypertension.Frontiers in endocrinology · 2025Observational
- CEBPB/POU2F2 modulates endothelin 1 expression in prehypertensive SHR vascular smooth muscle cells.Journal of molecular endocrinology · 2023Article
- The Causal Relationship between Endothelin-1 and Hypertension: Focusing on Endothelial Dysfunction, Arterial Stiffness, Vascular Remodeling, and Blood Pressure Regulation.Life (Basel, Switzerland) · 2021Review
- Blood Pressure-Lowering Effect of Wine Lees Phenolic Compounds Is Mediated by Endothelial-Derived Factors: Role of Sirtuin 1.Antioxidants (Basel, Switzerland) · 2021Article
- Polycythemia with Renal Cell Carcinoma and Normal Erythropoietin Level.Case reports in urology · 2019Article
- Nicousamide normalizes renovascular hypertension in two-kidney one-clip hypertensive rats.Biomedical reports · 2013Article
- Gene expression profiling on the molecular action of danshen-gegen formula in a randomized placebo-controlled trial of postmenopausal women with hypercholesterolemia.Evidence-based complementary and alternative medicine : eCAM · 2013Article
- Receptor tyrosine kinase Ephb6 regulates vascular smooth muscle contractility and modulates blood pressure in concert with sex hormones.The Journal of biological chemistry · 2012Article
- Neuro-endocrine regulation of blood pressure.Indian journal of endocrinology and metabolism · 2011Article
- Physiology of endothelin and the kidney.Comprehensive Physiology · 2011Review
- TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats.International journal of hypertension · 2011Article
- Regulation of blood pressure and salt homeostasis by endothelin.Physiological reviews · 2011Review
- Modulation of Gi Proteins in Hypertension: Role of Angiotensin II and Oxidative Stress.Current cardiology reviews · 2010Article
- Renal cell carcinoma and arterial hypertension.Clinical and experimental nephrology · 2009Article
- Novel use of ultrasound to examine regional blood flow in the mouse kidney.American journal of physiology. Renal physiology · 2009Article
- Attenuation of experimental hepatopulmonary syndrome in endothelin B receptor-deficient rats.American journal of physiology. Gastrointestinal and liver physiology · 2009Article
- Natriuretic peptides in cardiovascular diseases.Cellular & molecular biology letters · 2008Review
- Effects of statins on vascular function of endothelin-1.British journal of pharmacology · 2005Article
- Contribution of the endothelin and renin-angiotensin systems to the vascular changes in rats chronically treated with ouabain.British journal of pharmacology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelin-1 (ET-1) was first characterized as a potent vasoconstrictor and is overexpressed in the vasculature in different models of hypertension, such as deoxycorticosterone acetate-salt rats, Dahl salt-sensitive rats, and stroke-prone spontaneously hypertensive rats. Moreover, patients with moderate to severe hypertension present increased vascular levels of prepro-ET-1 mRNA. In addition to their blood pressure-lowering effects, ET receptor antagonists are able to reduce vascular growth. Recent data suggest the involvement of an inflammatory response in the effects of ET-1, which contributes to vascular remodeling and endothelial dysfunction. Increasing evidence underscores the potential therapeutic benefit of ET receptor antagonists in different hypertension-related complications, not only in essential hypertension, but also in patients with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.